Generic drugmaker Mylan NV moved quickly on Friday to pour cold water on published reports that Teva Pharmaceuticals Industries is considering a bid to acquire it.
Mylan last week announced a $29 billion offer to buy Perrigo Co Plc in a move that some analysts suggested was a tactic to help fend off an acquisition by larger rival Teva. Mylan Executive Chairman and former Chief Executive Officer Robert Coury said the Perrigo plans remain on track.
19:08 U.S. indicts three Takata executives, fines company $1 billion in faulty air bag scandal15
13:48 Wells Fargo Profit Falls 5.4% as Mortgage Revenue Declines23
13:21 Bank of America profits surge on cost cuts, trading gains24
13:16 Wells Fargo earnings: 96 cents per share, vs. expected EPS of $120